EcoDrugPlus

Amyloid-Beta A4 Protein

Ensembl ID : ENSLCAG00010020562
Gene Symbol: LOC108880432
4 Cross references
204 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSLCAG00010004166
Gene Symbol: LOC108882770
3 Cross references
206 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSLCAG00010023371
Gene Symbol: AR
4 Cross references
213 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSLCAG00010010122
Gene Symbol: AGTR1
4 Cross references
198 Possible Orthologues:

Angiotensin Ii Receptor, Type 2

Ensembl ID : ENSLCAG00010002306
Gene Symbol: AGTR2
1 Cross references
185 Possible Orthologues:

Apelin Receptor 2

Ensembl ID : ENSLCAG00010008214
Gene Symbol: APLNR2
1 Cross references
171 Possible Orthologues:

Arachidonate 12-Lipoxygenase

Ensembl ID : ENSLCAG00010011804
Gene Symbol: ALOX12
4 Cross references
199 Possible Orthologues:

Arachidonate 5-Lipoxygenase A

Ensembl ID : ENSLCAG00010004266
Gene Symbol: ALOX5A
1 Cross references
225 Possible Orthologues:

Arachidonate 5-Lipoxygenase-Activating Protein

Ensembl ID : ENSLCAG00010023939
Gene Symbol: ALOX5AP
1 Cross references
200 Possible Orthologues:

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSLCAG00010002209
Gene Symbol: AVPR1A
4 Cross references
195 Possible Orthologues:

Arginine Vasopressin Receptor 1aa

Ensembl ID : ENSLCAG00010006943
Gene Symbol: AVPR1AA
4 Cross references
170 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSLCAG00010019162
Gene Symbol: AVPR2
4 Cross references
178 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).